INCYTE CORP

Incyte’s stock surges 3% as its AI‑driven platform and pipeline strengthen, offering investors a stable entry point near a bullish 200‑day average.

Incyte stock dips 2.73% as it trades at $113.44, 4% above its 200‑day SMA—yet strong biotech pipeline and pharma partnerships keep investors optimistic about future growth.

Incyte’s latest 24‑hour stock snapshot: $116.62 per share, 9.15% drop from month‑end, 52‑week low $84.02. See how it compares to peers like WST, ZM, and OTIS.